In patients who have undergone allogeneic hematopoietic stem cell transplantation with myeloablative conditioning and have engrafted, how long should antifungal prophylaxis be continued?

Duration of Antifungal Prophylaxis Post-Engraftment in Myeloablative Allo-HSCT

In post-engrafted allogeneic HSCT patients with myeloablative conditioning who do not have GVHD, continue fluconazole until day +75; if steroid-treated acute GVHD develops, switch to mold-active prophylaxis with posaconazole and continue throughout the duration of significant immunosuppression. 1

Risk-Stratified Approach

The duration of antifungal prophylaxis after engraftment depends critically on whether the patient develops graft-versus-host disease requiring immunosuppression:

Patients WITHOUT GVHD (Lower Risk)

• Continue fluconazole 400 mg daily until day +75 1
• This represents the standard duration for patients who engraft successfully without complications
• The risk of invasive fungal disease decreases substantially after engraftment in the absence of ongoing immunosuppression 2

Patients WITH Steroid-Treated Acute GVHD (High Risk)

Switch to mold-active prophylaxis with one of the following 1:

• Posaconazole tablets: 300 mg daily (after loading dose of 300 mg twice daily on day 1) - Grade A-I recommendation
• Posaconazole oral solution: 200 mg three times daily - Grade A-I recommendation
• Voriconazole: 4 mg/kg twice daily (after loading) - Grade B-I recommendation
• Itraconazole - Grade B-I recommendation (with therapeutic drug monitoring)
• Isavuconazole: 200 mg daily (after loading) - Grade B-II recommendation, particularly useful if QTc prolongation or intolerance to other azoles

Continue mold-active prophylaxis throughout the period of augmented immunosuppression for GVHD treatment 1, 2. This typically extends well beyond day +75 and should continue as long as patients receive significant corticosteroids (≥20 mg prednisone equivalents daily) or other intensive immunosuppression 2.

Evidence Supporting This Approach

The 2025 ECIL guidelines 1 provide the most current and authoritative recommendations, explicitly stating that fluconazole can be continued until day +75 in patients without GVHD after engraftment. The 2018 ASCO/IDSA guidelines 2 similarly recommend continuing prophylaxis "postmyeloid reconstitution or engraftment after stem-cell transplantation, particularly in the setting of postengraftment augmented immunosuppression (for the treatment of GVHD)."

Recent research supports a risk-adapted approach. A 2024 study 3 found no difference in invasive mold infection rates at day +100 between patients who continued versus discontinued antifungal prophylaxis at hospital discharge, suggesting that universal extended prophylaxis may not be necessary in lower-risk patients. However, this study's findings support tailoring prophylaxis duration to individual risk factors rather than abandoning the day +75 standard entirely.

Critical Decision Points

The key clinical decision point is the development of acute GVHD requiring systemic corticosteroids. This fundamentally changes the risk profile and necessitates:

1. Immediate switch from fluconazole to mold-active prophylaxis
2. Extension of prophylaxis duration beyond day +75
3. Consideration of therapeutic drug monitoring for azoles 1

Common Pitfalls to Avoid

• Do not continue fluconazole alone in patients with steroid-treated GVHD - fluconazole lacks mold activity and receives a D-III (negative) recommendation in this setting 1
• Do not arbitrarily stop prophylaxis at day +75 in patients with ongoing GVHD - the risk period extends as long as significant immunosuppression continues 2
• Monitor for drug-drug interactions, particularly with calcineurin inhibitors and corticosteroids when using azole antifungals 1
• Ensure therapeutic drug monitoring for itraconazole, voriconazole, and posaconazole to maintain adequate serum concentrations 1

Practical Algorithm

Post-engraftment → Assess for GVHD
│
├─ No GVHD → Continue fluconazole 400 mg daily → Stop at day +75
│
└─ Acute GVHD requiring steroids → Switch to mold-active prophylaxis
                                    (posaconazole preferred)
                                    → Continue throughout immunosuppression
                                    → Monitor drug levels
                                    → Reassess if steroids taper below 20 mg/day

The day +75 endpoint for uncomplicated cases is well-established in guidelines 1, 2, while the presence of GVHD requiring immunosuppression mandates extended, mold-active prophylaxis for as long as the patient remains at high risk.